Moreover, investigation of the expression levels of EGFR, PD-L1, and TMEM16A in the early-stage HNSCC is necessary to confirm whether the target therapy we suggested in this review can be adopted in such an early disease. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.